Cellectar Biosciences to Present at the LD Micro Invitational

MADISON, WI and LOS ANGELES, CA / ACCESSWIRE / June 2, 2016 / Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 6th annual LD Micro Invitational on Thursday, June 9 at 9:30 AM PST/12:30 PM EST. Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.

“As we continue to successfully advance our operating plan and clinical programming, we remain committed to providing performance updates with existing and potential shareholders,” said Mr. Caruso. “The LD Micro Invitational conference provides an excellent venue to further share the Cellectar story and we are appreciative of the opportunity to participate.”

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small/micro-cap space.

View Cellectar Biosciences’ profile here: http://www.ldmicro.com/profile/CLRB

Profiles powered by LD Micro – News Compliments of Accesswire

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC Delivery Platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For additional information please visit www.cellectarbiosciences.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

SOURCE: Cellectar Biosciences via LD Micro

ReleaseID: 440662